BeOne Medicines (688235.SS) Stock Price

BeOne Medicines Price

SSE·CLOSED
248.02
​
Market closed

Revenue has compounded at 67.6% per year over the past 12 years to 36.84 B CNY. BeOne Medicines's net margin stands at 5.4%, up from -123.9% several years earlier. Analysts set a median price target of 370.68 CNY, implying 49.5% above the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus.

BeOne Medicines stock price

Access this data via the Eulerpool API

BeOne Medicines business model & stock analysis

Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company. The firm is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The firm has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects. The company has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The firm has in-licensed the rights to distribute 13 approved medicines for the China market.

Frequently asked questions about BeOne Medicines

Analysts currently set an average price target of 369.28 CNY for the BeOne Medicines stock (median: 370.68 CNY), implying +48.9 % versus the latest price. The consensus is based on 15 analyst ratings.

15 analysts currently rate the BeOne Medicines stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BeOne Medicines to generate revenue of 45.30 B CNY and earnings per share of 3.42 CNY.

Converted at the current exchange rate, the BeOne Medicines share trades at 33.06 EUR (248.02 CNY).

The BeOne Medicines share (688235.SS) is listed on 1 stock exchanges, including: Shanghai (688235.SS).

The expected revenue of BeOne Medicines is 45.30 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BeOne Medicines is 5.13 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BeOne Medicines is currently 72.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BeOne Medicines stock.

The price-to-sales ratio (P/S) of BeOne Medicines is currently 8.21. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BeOne Medicines stock.

The Eulerpool Quality Score for BeOne Medicines is 7/10.

The ISIN of BeOne Medicines is CNE100005XT6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BeOne Medicines is 688235.SS. The ticker symbol is used to trade BeOne Medicines shares on the stock exchange.

Fair ValueTerminal
245.54 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
4.00 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website beigene.com
Country
Cayman Islands
Currency
CNY
Initial public offering
Feb 3, 2016
ISIN
CNE100005XT6
Cusip
G0956V108
Market capitalization
339.21 B CNYMega Cap
52-Week Range
PEG
2.33
P/E ratio
P/Ee 2026
66.10
P/Ee 2027
48.05
P/Ee 2028
35.18
P/Ee 2029
30.03
P/Ee 2030
24.53
P/Se
8.21
EV/EBIT
110.02
P/B Ratio
11.60
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.77 %
Last updated Oct 12, 2026, 7:12 PM

BeOne Medicines Peer Group

BeOne Medicines Ticker

SHH · 688235.SS

BeOne Medicines FIGI

688235:CH · BBG00C3RCCG3688235:CG · BBG00Z3T2MQ6688235:C1 · BBG01FRBB6F9